- Home
- LXP vs AGIO Comparison
LXP vs AGIO Comparison
Compare LXP & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXP
- AGIO
- Stock Information
- Founded
- LXP 1993
- AGIO 2007
- Country
- LXP United States
- AGIO United States
- Employees
- LXP N/A
- AGIO N/A
- Industry
- LXP Real Estate Investment Trusts
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- LXP Real Estate
- AGIO Health Care
- Exchange
- LXP Nasdaq
- AGIO Nasdaq
- Market Cap
- LXP 2.5B
- AGIO 2.1B
- IPO Year
- LXP 1993
- AGIO 2013
- Fundamental
- Price
- LXP $9.11
- AGIO $36.42
- Analyst Decision
- LXP Hold
- AGIO Buy
- Analyst Count
- LXP 3
- AGIO 6
- Target Price
- LXP $10.50
- AGIO $57.00
- AVG Volume (30 Days)
- LXP 2.7M
- AGIO 762.4K
- Earning Date
- LXP 11-05-2025
- AGIO 10-30-2025
- Dividend Yield
- LXP 5.89%
- AGIO N/A
- EPS Growth
- LXP 203.57
- AGIO N/A
- EPS
- LXP 0.27
- AGIO 11.13
- Revenue
- LXP $363,003,000.00
- AGIO $40,875,000.00
- Revenue This Year
- LXP N/A
- AGIO $23.66
- Revenue Next Year
- LXP $5.19
- AGIO $143.65
- P/E Ratio
- LXP $33.93
- AGIO $3.35
- Revenue Growth
- LXP 6.63
- AGIO 30.57
- 52 Week Low
- LXP $6.85
- AGIO $23.42
- 52 Week High
- LXP $10.33
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- LXP 60.53
- AGIO 47.14
- Support Level
- LXP $9.10
- AGIO $35.72
- Resistance Level
- LXP $9.28
- AGIO $37.18
- Average True Range (ATR)
- LXP 0.16
- AGIO 1.58
- MACD
- LXP -0.01
- AGIO -0.14
- Stochastic Oscillator
- LXP 50.88
- AGIO 44.29
About LXP LXP Industrial Trust (Maryland REIT)
LXP Industrial Trust is a real estate investment trust principally involved in the ownership of equity and debt investments in single-tenant properties and land throughout the United States. The majority of the revenue is earned through rental revenue.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.